Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Sicca Syndrome or Sjogren’s syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease.

The Sicca Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Sicca Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Sicca Syndrome and features dormant and discontinued projects.

Sicca Syndrome Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Sicca Syndrome pipeline drugs market are Tumor Necrosis Factor Receptor Superfamily Member 13C, Tumor Necrosis Factor Receptor Superfamily Member 5, CD40 Ligand, Cells Expressing B Cell Receptor CD22, and Others. Tumor Necrosis Factor Receptor Superfamily Member 13C leads this segment of the Sicca Syndrome pipeline drugs market.

Sicca Syndrome Pipeline Drugs Market Analysis, by Targets

For more Sicca Syndrome pipeline drugs market target insights, download a free report sample

Sicca Syndrome Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Sicca Syndrome pipeline drugs market are Tumor Necrosis Factor Receptor Superfamily Member 13C Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, CD40 Ligand Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Others. Tumor Necrosis Factor Receptor Superfamily Member 13C Antagonist leads the Sicca Syndrome pipeline drugs market in terms of MoA.

Sicca Syndrome Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the Sicca Syndrome pipeline drugs market, download a free report sample

Sicca Syndrome Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Sicca Syndrome pipeline drugs market are subcutaneous, intravenous, oral, parenteral, and others. Subcutaneous leads the Sicca Syndrome pipeline drugs market in terms of RoA.

Sicca Syndrome Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Sicca Syndrome pipeline drugs market, download a free report sample

Sicca Syndrome Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Sicca Syndrome pipeline drugs market are monoclonal antibody, small molecule, fusion protein, biologic, and others. Monoclonal Antibody leads the Sicca Syndrome pipeline drugs market in terms of molecule types.

Sicca Syndrome Pipeline Drugs Market Analysis, by Molecule Types

For more molecule-type insights into the Sicca Syndrome pipeline drugs market, download a free report sample

Sicca Syndrome Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Sicca Syndrome pipeline drugs market are Novartis AG, Alpine Immune Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, and Rise Therapeutics LLC among others. Novartis AG has the highest number of products under development.

Sicca Syndrome Pipeline Drugs Market Analysis, by Companies

To know more about the Sicca Syndrome pipeline drugs market companies, download a free report sample

Sicca Syndrome Pipeline Drugs Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome.
• The pipeline guide reviews pipeline therapeutics for Sicca Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Sicca Syndrome therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Sicca Syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Sicca Syndrome

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Sicca Syndrome pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.